February 6, 2017 / 6:30 AM / a year ago

BRIEF-Ablynx submits marketing authorisation for caplacizumab

Feb 6 (Reuters) - Ablynx NV :

* Ablynx submits a marketing authorisation application to the European medicines agency for caplacizumab, its anti-vwf nanobody, for the treatment of aTTP

* Ablynx is on track to report results of the confirmatory phase III HERCULES study in the second half of 2017

* In phase II TITAN study, treatment with caplacizumab significantly reduced time to platelet count normalisation and number of recurrences of aTTP while on drug treatment

* Intends to lead the commercialisation of caplacizumab in Europe and North America

* Post-Hoc analysis of the TITAN study demonstrated that caplacizumab dramatically reduced the number of patients experiencing major thromboembolic events while on drug treatment Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below